Action of novel CD37 antibodies on chronic lymphocytic leukemia cells

Leukemia

Volumn 26, Issue 3, 2012, Pages 546-549

  Krause, G ^a   Patz, M ^a   Isaeva, P ^a   Wigger, M ^a   Baki, I ^a   Vondey, V ^a   Kerwien, S ^a   Kuckertz, M ^a   Brinker, R ^a   Claasen, J ^a   Frenzel, L P ^a   Wendtner, C M ^a   Heider, K H ^b   Hallek, M ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD20 ANTIGEN; CD37 ANTIGEN; CD52 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 37.1; MONOCLONAL ANTIBODY 37.2; RITUXIMAB; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFECTION RISK; LETTER; LEUKEMIA CELL; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; CELLS, CULTURED; HUMANS; IMMUNOGLOBULIN G; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE DEPLETION; RECOMBINANT FUSION PROTEINS; TETRASPANINS;

EID: 84857996061     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.233     Document Type: Letter

References (9)

1. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, openlabel, phase 3 trial. Lancet 2010; 376: 1164-1174.
2. Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 2010; 116: 3705-3714.
3. Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 2007; 110: 2569-2577. (Pubitemid 47527052)
4. Furman RR, Andritsos L, Flinn IW, Forero-Torres A, Foon KA, Pagel JM et al. Phase 1 Dose escalation study of TRU-016, an anti-CD37 SMIPTM protein in relapsed and refractory CLL. Blood 2010; 116: 56.
5. Heider K-H, Kiefer K, Ostermann E, Lamche E, Küpcü Z, Jacobi A et al. Novel Fc-engineered antibodies to 37 with pro-apoptotic and enhanced ADCC activity. Blood 2010; 116: 3916.
6. Patz M, Isaeva P, Forcob N, Muller B, Frenzel LP, Wendtner CM et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol 2011; 152: 295-306.
7. Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in Blymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 2004; 83: 634-645. (Pubitemid 39317488)
8. Voso MT, Pantel G, Rutella S, Weis M, D'Alo F, Urbano R et al. Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica 2002; 87: 918-925.
9. van Spriel AB, Puls KL, Sofi M, Pouniotis D, Hochrein H, Orinska Z et al. A regulatory role for CD37 in T-cell proliferation. J Immunol 2004; 172: 2953-2961. (Pubitemid 38263682)